

Span Divergent Ltd.

(Formerly Span Diagnostics Ltd.)
9th Floor, Rajhans Bonista,
Behind Ram Chowk, Ghod Dod Road,

Surat - 395 007, Gujarat, India Phone: +91 261 266 32 32 E-Mail: contact@span.in

Date: February 09, 2023

To, Listing Compliance Department Bombay Stock Exchange Limited Phiroze Jeejeebhoy Tower, 25th Floor Dalal Street, Mumbai – 400 001

Respected Sir,

Subject: Unaudited Financial Results for the Quarter December 31, 2022

Scrip Code: 524727

We are pleased to forward herewith Unaudited Financial Results (Both Standalone Financial Results & Consolidated Financial Results) of the Company for the quarter ended on December 31, 2022 along with Limited Review Reports (Both Standalone Financial Results & Consolidated) in compliance with the requirement of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The said financial results have been approved by Board of Directors at their meeting held on February 09, 2023.

We are also arranging to publish in newspaper.

You are therefore requested to take the above information on records.

Thanking You.

Yours faithfully,

For Span Divergent Limited

Viral P Desai Managing Director DIN 00021929

Encl: As above

CIN: L74999GJ1980PLC003710

www.span.in

(Formerly known as Span Diagnostics Limited)

Regd.Office: 9th Floor, 902-904, Rajhans Bonista, Behind Ram Chowk Temple, Ghod Dod Road, Surat-395007

CIN:L74999GJ1980PLC003710

Statement of Standalone Unaudited Results for the Quarter and Nine Months ended December 31, 2022.

(Rs. In Lakhs)

		Standalone					
	Particulars	Three Months			Nine Months		
Sr. No.		Quarter ended 31 December 2022	Quarter ended 30 September 2022	Quarter ended 31 December 2021	Period ended 31 December 2022	Period ended 31 December 2021	Year ended 31 Mar 2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from operations						
	Sale of Traded Products	-	-	-	-	-	-
	Other Operating Income - from Subsidiaries	50.42	51.25	49.89	147.88	140.54	196.42
	Other income	21.27	22.07	18.26	59.70	96.50	115.42
	Total income	71.69	73.32	68.15	207.58	237.04	311.84
2	Expenses						
	Employee benefit expense	24.15	24.91	31.66	73.07	85.23	114.21
	Finance costs	-	-	-	-	-	-
	Depreciation and amortisation expense	10.71	10.68	14.22	31.98	42.65	50.90
	Other expenses	8.91	15.13	7.60	31.18	25.11	36.72
	Total expenses	43.77	50.72	53.49	136.23	152.99	201.83
	Profit / (Loss) before tax and Exceptional items (1-2)	27.92	22.60	14.67	71.35	84.04	110.01
	Exceptional items	-	(110.83)	-	(110.83)	-	(917.47)
5	Profit/(Loss) before tax (3-4)	27.92	(88.23)	14.67	(39.48)	84.04	(807.46)
6	Tax expense:						
	- Current tax	-		-	-	-	-
	- Deferred tax	1.38	0.85	0.58	2.63	(32.48)	(31.66)
	Profit/(Loss) for the period after tax (5-6)	26.54	(89.08)	14.10	(42.11)	116.52	(775.80)
8	Other comprehensive income Item that will not be reclassified to Profit or Loss (Consisting of re-measurement of net defined benefit liabilities)	0.09	0.09	0.27	0.26	0.80	0.34
	Income tax relating to items that will not be reclassified to Profit or Loss	(0.02)	(0.02)	(0.07)	(0.07)	(0.22)	(0.09)
9	Total comprehensive income for the year (7+8)	26.61	(89.01)	14.29	(41.92)	117.10	(775.55)
10	Paid-up equity share capital (Face value of Rs. 10/-each)	546.17	546.17	546.17	546.17	546.17	546.17
11	Reserves (Excluding revaluation reserves)						2,982.47
12	Earnings per equity share for profit from operation						
	Basic earnings per share *	0.49	(1.63)	0.26	(0.77)	2.13	(14.20)
	Diluted earnings per share *	0.49	(1.63)	0.26	(0.77)	2.13	(14.20)

^{*} For the period only and not annualised

Note : -

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 09, 2023.
- 2 The financial results of the Company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013 read with the relevant rules of the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) Rules, 2016.
- 3 Other Operating Income comprises of Interest on fluctuating capital provided by the Company to it's LLP subsidiaries and management fees income which is based on the revenue earned by subsidiaries during the quarter.
- 4 In case of subsidiary:In case of subsidiary:

(a) Aranya Agri Biotech LLP had accumulated losses of Rs.14.10 Crores till March 31 2022 and Rs. 55.48 lacs in the current year up to December 31, 2022. The Management has decided to impair the investment and Rs.12.22 Crores are provided in the books of the Company and are treated as an exceptional item during the year. Notwithstanding the above, the financial results of the LLP have been prepared on going concern basis as Management has initiated exercise to reorganize business structure.

(b) Biospan Scientific LLP had accumulated losses of Rs.1.57 Crores as at 31st March 2019, resulting in substantial erosion in the net worth of the LLP. Hence the Management had decided to impair the investment and Rs. 1.83 Crores were provided in the books of the Company and was treated as an exceptional item during the year 2018-19. Notwithstanding the above, the financial results of the LLP has been prepared on going concern as the business has been showing promising results and management endeavours to be able to establish profitable operation.

(c) Biospan Contamination Control Solution Pvt. Ltd had accumulated losses of Rs. 4.97 Crores till December 31, 2022. As on that date the subsidiary Company's total liabilities exceeded its total assets by Rs. 4.87 Crores. Notwithstanding the above, the financial results of the subsidiary Company has been prepared on going concern basis as Management believes that the Company would be able to establish profitable operation and the losses incurred is attributed to factors of short term nature. Further, Management is reasonably confident that with appropriate product license, the Company will achieve adequate revenue and negative net worth would turn positive by 2023.

- 5 In pursuance to Section 115BAA of the Income Tax Act, 1961 announced by Government of India through Taxation Laws (Amendment) Ordinance, 2019, the Company has an irrevocable option of shifting to a lower tax rate along with consequent reduction in certain tax incentive including additional depreciation and accumulated depreciation. The Company is evaluating this option and continues to recognise the taxes on income for the quarter and nine months ended 31st December 2022 as per the earlier provisions.
- 6 The Company has primarily engaged in the business of investing in it's subsidiaries. There are no separate reportable segment as per Ind AS 108 Operating segments.
- 7 Previous quarters and periods figures have been regrouped and rearranged wherever necessary.

For, SPAN DIVERGENT LIMITED

Mr. Viral Desai Managing Director DIN: 00029219

Place : Surat

Date: February 09, 2023

Span Divergent Limited
(Formerly known as Span Diagnostics Limited)
Regd.Office: 9th Floor,902-904, Rajhans Bonista, Behind Ram Chowk Temple,Ghod Dod Road, Surat-395007
CIN:L74999GJ1980PLC003710

Statement of Consolidated Unaudited Results for the Quarter and Nine Months ended December 31, 2022.

		Consolidated			(Rs.In Lakhs)		
	Particulars	Three Months			Nine Months		
Sr. No.		Quarter ended 31 December 2022	Quarter ended 30 Sepetember 2022	Quarter ended 31 December 2021	Period ended 31 December 2022	Period ended 31 December 2021	Year ended 31 March 2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from operations						
	Sale of Traded Products/Services	313.58	295.97	306.63	868.50	1,029.20	1,295.03
	Other Operating Income	18.50	14.38	_	43.38	_	13.75
	Other income	16.30	22.84	17.01	46.62	146.39	164.28
	Total income	348.38	333.19	323.65	958.50	1,175.59	1,473.06
2	Expenses					,	,
	Cost of materials consumed	0.63	3.13	0.34	1.48	233.14	232.22
	Purchases of stock-in-trade	44.44	20.13	35.40	72.07	191.29	209.33
	Changes in inventories of work-in-progress, stock-in-trade	14.42			41.41		
	and finished goods		17.87	(1.85)		(79.52)	(80.33)
	Employee benefit expense	58.24	65.21	79.84	183.37	201.49	265.38
	Finance costs	19.68	18.89	22.92	64.70	85.79	108.04
	Depreciation and amortisation expense	55.29	53.53	68.14	164.16	161.63	216.71
l	Other expenses	182.57	204.68	160.69	508.95	486.48	641.15
	Total expenses	375.27	383.44	365.48	1,036.14	1,280.30	1,592.51
3	Profit / (Loss) before tax and Exceptional items (1-2)	(26.89)	(50.25)	(41.83)	(77.64)	(104.71)	(119.44)
4	Exceptional items	_	(110.83)		(110.83)	_	(917.47)
5	Profit/(Loss) before tax (3-4)	(26.89)	(161.08)	(41.83)	(188.47)	(104.71)	(1,036.91)
6	Tax expense:	(, , , ,	<u> </u>	(****)	,	,	,
	- Current tax	-		-	-	-	
ii	- Deferred tax	(1.19)	(2.13)	(1.42)	(7.69)	(18.17)	(21.63)
7	Profit/(Loss) for the period after tax (5-6)	(25.70)	(158.95)	(40.41)	(180.78)	(86.55)	(1,015.28)
	Profit for the year attributable to:		<u> </u>				
	(a) Owners of the Company	(12.93)	(150.63)	(31.77)	(154.54)	(59.09)	(980.01)
	(b) Non Controlling Interest	(12.77)	(8.32)	(8.63)	(26.24)	(27.46)	(35.27)
		(25.70)	(158.95)	(40.41)	(180.78)	(86.55)	(1,015.28)
8	Other comprehensive income						
,	Item that will not be reclassified to Profit or Loss (Consisting of re-measurement of net defined benefit liabilities)	0.36	0.39	2.10	1.09	3.66	1.56
	Income tax relating to items that will not be reclassified to Profit or Loss	(0.11)	(0.13)	(0.68)	(0.26)	(1.17)	(0.49)
	Other comprehensive income	0.25	0.26	1.42	0.83	2.50	1.07
	Other comprehensive income attributable to:						ĺ
	(a) Owners of the Company	0.23	0.18	1.35	0.76	2.47	0.72
	(b) Non Controlling Interest	0.02	0.08	0.07	0.08	0.02	0.11
		0.25	0.26	1.42	0.84	2.49	0.83
<u> </u>	Total community in come for the control (7, 0)	/OF 4.5	(450.10)	(00.00)	(470.00	(04.52)	(4.044.53)
9	Total comprehensive income for the year (7+8)	(25.44)	(158.69)	(38.98)	(179.96)	(84.06)	(1,014.21)
1	Total comprehensive income attributable to:	(10.40)	(150.40)	(20.40)	(150.70)	(F/ /3)	(070.05)
l	(a) Owners of the Company	(12.69)	(150.40)		(153.79)	(56.62)	(979.05)
<u> </u>	(b) Non Controlling Interest	(12.75)	(8.29)	(8.56)	(26.17)	(27.44)	(35.16)
		(25.44)	(158.69)	(38.98)	(179.96)	(84.06)	(1,014.21)
10	Paid-up equity share capital (Face value of Rs. 10/- each)	546.17	546.17	546.17	546.17	546.17	546.17
11	Reserves (Excluding revaluation reserves)						(324.09)
12	Earnings per equity share for profit from operation						
	Basic earnings per share *	(0.47)	(2.91)	(0.74)	(3.31)	(1.58)	(18.59)
	Diluted earnings per share *	(0.47)	(2.91)	(0.74)	(3.31)	(1.58)	(18.59)
* For	the period only and not annualised		•				

Note:

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 09, 2023.
- The financial results of the Company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013 read with the relevant rules of the Companies (Indian Accounting Standards) (Rules, 2016 as amended by the Companies (Indian Accounting Standards) (Amendment) Rules, 2016.
- The corresponding figures for the quarter and nine months ended December 31, 2022 have been approved by the Board of Directors, but have not been subject to review by the statutory auditors. Figures for the year ended 31st March 2022 are audited by the statutory auditors of the Group.

4

In case of subsidiary: In case of subsidiary:

- (a) Aranya Agri Biotech LLP had accumulated losses of Rs.14.10 Crores till March 31 2022 and Rs. 55.48 lacs in the current year up to December 31, 2022. The Management has decided to impair the investment and Rs.12.22 Crores are provided in the books of the Company and are treated as an exceptional item during the year. Notwithstanding the above, the financial results of the LLP have been prepared on going concern basis as Management has initiated exercise to reorganize business structure.
- (b) Biospan Scientific LLP had accumulated losses of Rs.1.57 Crores as at 31st March 2019, resulting in substantial erosion in the net worth of the LLP. Hence the Management had decided to impair the investment and Rs. 1.83 Crores were provided in the books of the Company and was treated as an exceptional item during the year 2018-19. Notwithstanding the above, the financial results of the LLP has been prepared on going concern as the business has been showing promising results and management endeavours to be able to establish profitable operation.
- (c) Biospan Contamination Control Solution Pvt. Ltd had accumulated losses of Rs.4.97 Crores till December 31, 2022. As on that date the subsidiary Company's total liabilities exceeded its total assets by Rs. 4.87 Crores. Notwithstanding the above, the financial results of the subsidiary Company has been prepared on going concern basis as Management believes that the Company would be able to establish profitable operation and the losses incurred is attributed to factors of short term nature. Further, Management is reasonably confident that with appropriate product license, the Company will achieve adequate revenue and negative net worth would turn positive by 2023.
- In pursuance to Section 115BAA of the Income Tax Act, 1961 announced by Government of India through Taxation Laws (Amendment) Ordinance, 2019, the Company has an irrevocable option of shifting to a lower tax rate along with consequent reduction in certain tax incentive including additional depreciation and accumulated depreciation. The Company is evaluating this option and continues to recognise the taxes on income for the quarter and period ended December 31, 2022 as per the earlier provisions.
- 6 Previous quarters and periods figures have been regrouped and rearranged wherever necessary.
- The above is an extract of the detailed format of financial results filed with Stock Exchange under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of financial results are available on the Stock Exchange website www.bseindia.com and on Company's website www.spandivergent.in.

For, SPAN DIVERGENT LIMITED

Place : Surat

Date: February 09, 2023

Mr. Viral Desai Managing Director DIN: 00029219 8. Consolidated Segment Revenue, Results Assets and Liability as at December 31, 2022

	Particulars	Consolidated (Rs.In Lakhs)					
		Three Months			Nine Months		
Sr. No.		Quarter ended 31 December 2022	Quarter ended 30 Sepetember 2022	Quarter ended 31 December 2021	Period ended 31 December 2022	Period ended 31 December 2021	Year ended 31 March 2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Segment Revenue						
	- Cashew processing	234.08	257.32	260.28	720.29	938.83	1,163.29
	- Tissu Culture	2.65	56.53	2.89	62.19	55.56	26.95
	- Trading	79.76	45.74	47.66	164.52	134.68	186.38
	Gross Revenue from Operations from Segments	316.49	359.59	310.82	946.99	1,129.05	1,376.62
	Less : Inter Segment Revenue				-		
	Net Revenue from Operations from Segments	316.49	359.59	310.82	946.99	1,129.05	1,376.62
2	Segment Results				-		
	Profit / (Loss) before Interest and tax				-		
	- Cashew processing	(23.45)	(29.80)	0.07	(54.34)	(27.57)	(41.83
	- Tissu Culture	(14.16)	(21.02)	(42.39)	(44.61)	(81.76)	(141.81
	- Trading	(17.26)	(11.30)	(64.24)	(39.53)	(91.78)	(46.32
	- Unallocable Income over expenses like (Including HO)	27.98	98.97	64.74	(50.08)	65.18	(806.95
	Total Profit / (Loss) before Tax	(26.89)	(161.08)	(41.82)	(188.47)	(104.71)	(1,036.91
3	Segment Assets				-		
	- Cashew processing	1,275.53	1,287.71	1,470.01	1,275.53	1470.01	1,436.77
	- Tissu Culture	240.85	225.31	240.85	240.85	240.85	223.20
	- Trading	245.58	212.46	226.67	245.58	226.67	228.94
	- Unallocable	5,262.59	889.48	5,164.84	5,262.59	5,164.84	893.66
	Total Assets	7,024.56	2,614.96	7,102.37	7,024.55	7,102.37	2,782.57
4	Segment Liability				-		
	- Cashew processing	922.77	682.60	1,074.70	922.77	1074.70	766.50
	- Tissu Culture	284.66	44.45	284.66	284.66	284.66	114.77
	- Trading	649.36	602.06	581.64	649.36	581.64	593.47
	- Unallocable	1,648.63	1,733.51	557.01	1,648.63	557.01	1,600.98
	Total Liability	3,505.43	3,062.62	2,498.01	3,505.42	2,498.01	3,075.72

: 2474242 : 2465851

: 2465852 ax : 2464054

1 / 573, 1st FLOOR, GAJANAND COMPLEX, POR MOHALLOW, NEAR ANAND HOSPITAL, NANPURA, SURAT - 395 001.

Independent Auditor's Review Report on the Quarterly and Year to Date
Unaudited Standalone Financial Results of the Company Pursuant to the
Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015, as amended

Review Report to
To the Board of Directors of
Span Divergent Ltd.

- 1. We have reviewed the accompanying statement of unaudited standalone financial results ('the Statement') of Span Divergent Ltd ('the Company') for the quarter and nine month ended 31st December, 2022 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
- 2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as

amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Y. B. Desai and Associates Chartered Accountants Firm Registration No. 102368W

Desai & A

SURA

ed Accou

Mayank Y. Desai Partner

Membership No. :- 108310

UDIN: 23108310BGWRJC7243

Date :- 9th February, 2023

Place :- Surat



: 2474242 : 2465851 : 2465852

: 2465852 ax : 2464054

1 / 573, 1st FLOOR, GAJANAND COMPLEX, POR MOHALLOW, NEAR ANAND HOSPITAL, NANPURA, SURAT - 395 001.

Independent Auditor's Review Report on Quarterly and Year to Date Unaudited
Consolidated Financial Results of the Company Pursuant to the Regulation 33 of
the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as
amended)

Review Report to

The Board of Directors

Span Divergent Ltd.

- 1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Span Divergent Ltd ('the Holding Company') and its subsidiary (the Holding Company and its subsidiary together referred to as 'the Group') for the quarter and nine month ended on 31st December, 2022 attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
- 2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), to the extent applicable.

4. The Statement includes the results of the following entities:

Parent Company:

i. Span Divergent Limited



Subsidiary:

- Dryfruit Factory LLP
- · Aranya Agri Biotech LLP
- Desai Farmharvest LLP
- Span Diagnostics LLP
- Biospan Scientific LLP
- Biospan Contamination Control Solutions Pvt Ltd
- 5. The accompanying Statement includes the unaudited interim financial results and other unaudited financial information, in respect of subsidiary have been reviewed by their respective independent auditor.

The independent auditor's reports on interim financial results of this entity have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of this subsidiary, is based solely on the report of such auditor and procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement in respect of above matter is not modified with respect to our reliance on the work done and the reports of the other auditor.

6. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

esai & A

SURAT-

ed Accoun

For Y. B. Desai and Associates Chartered Accountants Firm Registration No. 102368W

> Mayank Y. Desai Partner

Membership No.: - 108310

UDIN: 231083108 GWRJD8801

Date:- 9th February, 2023

Place :- Surat